Evidence map›Paper›PMID 34827213›Full record

ArticleAntibiotics (Basel, Switzerland)2021

Antibacterial Activity of Kaolin-Silver Nanomaterials: Alternative Approach to the Use of Antibiotics in Animal Production.

Lara Pérez-Etayo, David González, José Leiva, María Díez-Leturia, Alba Ezquerra, Luis Lostao, Ana Isabel Vitas

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lara Pérez-EtayoDepartment of Microbiology and Parasitology, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0003-4455-8148
David GonzálezDepartment of Microbiology and Parasitology, University of Navarra, 31008 Pamplona, Spain.
José LeivaMicrobiology Service, Clínica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain.
María Díez-LeturiaDepartment of Microbiology and Parasitology, University of Navarra, 31008 Pamplona, Spain.
Alba EzquerraENOSAN Laboratories, 50018 Zaragoza, Spain.
Luis LostaoENOSAN Laboratories, 50018 Zaragoza, Spain.
Ana Isabel VitasDepartment of Microbiology and Parasitology, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-8242-4496
Navarre Institute of Health Research · ESUniversidad de Navarra · ESClinica Universidad de Navarra · ES

Funding

European Regional Development Fund (ERDF) through the Interreg V-A Spain-France-Andorra programme (POCTEFA 2014-2020, cofinancing rate 65%) INTERREG POCTEFA EFA183/16/OUTBIOTICS
6 · The paper itself

Abstract

According to the search for alternatives to replace antibiotics in animal production suggested in the antimicrobial resistance action plans around the world, the objective of this work was to evaluate the bactericidal effect of kaolin-silver nanomaterial for its possible inclusion as an additive in animal feed. The antibacterial activity of the C3 (kaolin-silver nanomaterial) product was tested against a wide spectrum of Gram-negative and Gram-positive bacteria (including multidrug resistant strains) by performing antibiograms, minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC), as well as growth inhibition curves against seven strains causing infections in animals. The C3 product generated inhibition halos in all the tested strains, and a higher activity against Gram-negative bacteria was found, with MBC values ranged from 7.8 µg/mL (

Indexed as

additivesanimal productionantimicrobial resistancefeednanomaterialssilver

Identifiers

PMID34827213
PMCPMC8614645
OpenAlexW3205696005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.